Inhibition of the innate immune system to disrupt “Don’t Eat Me” signals between tumor and macrophages is a rapidly growing area of drug development. LILRB1 and LILRB2 are two such immunomodulatory receptors but targeting them poses the challenges of avoiding ten highly homologous LILR family members that are also expressed on myeloid cells. This presentation provides a rational and successful approach for overcoming these challenges utilizing a fully human, highly diverse antibody phage display library. It will also cover the next stages of antibody discovery and development, reviewing the in vitro and in vivo characterization required to go from antibody discovery to clinical candidate.
About the speaker:
Kalyani is a protein biochemist with extensive industry experience in antibody/protein biophysical characterization and assay development with special focus on biosensor/label-free methodologies. Kalyani currently manages the Biosensor and Protein Sciences teams out of the South San Francisco Antibody Discovery site, where her team supports production and analytical characterizations of antibodies, antibody fragments, bispecifics, etc.
Registration is open!
Monoclonal antibody discovery has been a foundational innovation that continues to drive novel antibody therapeutics in research areas including cancer, autoimmune disease, and infectious disease. As the demands and requirements for new antibodies continue to evolve, especially around safety, efficacy, and functional characterization, more powerful screening technologies are critical to antibody discovery and therapeutic development success. Unlike hybridoma and display technologies that can limit antibody diversity, have low campaign success, and require months to perform, the Beacon® optofluidic technology enables rapid selection of lead candidates by serial function-first screening of single B cells to increase success rates and shorten antibody discovery timelines to days.
This presentation will first highlight Bruker Cellular Analysis’ full Beacon antibody discovery suite for screening primary plasma cells and memory B cells, including the newest ability to discover antibody hits based on relative binding affinity, and share how customers can leverage optofluidic technology to rapidly discover high value monoclonal antibodies with the highest chances of success and fastest turnaround times.
The second half of this presentation will highlight how GenScript uses the Beacon optofluidic system for initial single B cell screening, followed by the state-of-the-art ProSpeed expression system for rapid re-expression and enabling world-class antibody characterization. Genscript’s ProSpeed™ single B cell screening service transforms lead characterization, including deep functional antibody profiling and enhanced BCR sequence recovery, making it faster and more cost effective than traditional plasmid-based expression systems.
Registration is open!
About the speakers:
Vincent Pai, Director, Product Management, Bruker Cellular Analysis
Vincent Pai is Director of Product Management at Bruker Cellular Analysis. He has over 10 years of experience in cell biology, nanotechnology, and microfluidics, with a background from UC San Diego and Massachusetts General Hospital in Boston. He now leads new product development for antibody discovery applications on the Beacon® optofluidic system.
Yu Liang, PhD, VP of Ab Drug Discovery, GenScript ProBio
Dr. Yu Liang received his Ph.D. degree in Virology/Microbiology from the University of Chicago and completed his postdoctoral training at NIAID, NIH. He then joined Novartis Inst. for Biomedical Research as a PI/lab head, and WuXi Biologics Discovery as Portfolio Director and Senior Project Leader. Currently he serves as VP of Ab Drug Discovery at GenScript ProBio, a global CDMO company providing end-to-end service from discovery to commercialization in cell and gene therapy (CGT), vaccine and antibody protein drug, to accelerate drug development for global customers. Dr. Liang has over 20 years of research experience in biomedical science in both academia and industry. His broad and in-depth knowledge & experience covers cellular / molecular biology, infectious diseases and molecular virology, viral/ tumor immunology and immunotherapy, and early phase drug discovery of bio-therapeutics, with special expertise in the discovery of therapeutic modalities based on therapeutic Abs (mAbs, BsAbs, ADCs, etc.).
Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.
Our selection of On Demand webinars can be viewed here.
Our YouTube channel includes selected webinars as well as recordings of our Symposia on topics such as:
- Computational Antibody Discovery: State of the Art
- Biopharmaceutical Informatics
- Harnessing Cytokines for Cancer Immunotherapy
- Emerging Immunotherapeutics for Ovarian Cancer Symposium
- Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells
